Pembrolizumab: all 1,753 studies that test it
Page 17 of 18. Open to participants first (418), then studies with results posted, then the rest; newest registration first within each.
- Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland TumorsActive, not recruitingNCT03360890Phase 2
- Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCCCompletedNCT03347292Phase 1
- Pembrolizumab as Neoadjuvant Treatment in HCCStatus unknownNCT03337841Phase 2
- A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin LymphomaActive, not recruitingNCT03331731Phase 2
- Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and NeckWithdrawnNCT03325465Phase 2
- T-Cell PET Imaging With [18F]F-AraG in Lung CancerWithdrawnNCT03311672Phase 2
- A Study of Pembrolizumab in Combination With Epacadostat in Women With Recurrent/Metastatic Endometrial CarcinomaWithdrawnNCT03310567Phase 2
- Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid LeukemiaWithdrawnNCT03291353Early Phase 1
- Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBCCompletedNCT03289819Phase 2
- Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHLActive, not recruitingNCT03283137Phase 1
- Denosumab and Pembrolizumab in Clear Cell Renal CarcinomaStatus unknownNCT03280667Phase 2
- Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)CompletedNCT03277638Phase 1/2
- Pembrolizumab in Combination With Doxorubicin in Advanced, Recurrent or Metastatic Endometrial CancerCompletedNCT03276013Phase 2
- A Study of ADXS-NEO Expressing Personalized Tumor AntigensTerminatedNCT03265080Phase 1
- Biomarkers in Urothelial Cancer Patients Treated With PembrolizumabStatus unknownNCT03263039Phase 2
- Pembrolizumab in Biliary Tract CancerCompletedNCT03260712Phase 2
- A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsCompletedNCT03260322Phase 1
- Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric CancerActive, not recruitingNCT03257163Phase 2
- Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid CancersTerminatedNCT03254732Phase 1
- Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cmStatus unknownNCT03254004Phase 2
- Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SDTerminatedNCT03246685Phase 2
- Anti-platelet + Pembro for H&N TumorsCompletedNCT03245489Phase 1
- Pembrolizumab in Combination With Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)WithdrawnNCT03245177Phase 1
- Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial CancerActive, not recruitingNCT03244384Phase 3
- A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 TherapyWithdrawnNCT03238638Phase 2
- QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsActive, not recruitingNCT03228667Phase 2
- Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally AdvancedActive, not recruitingNCT03225664Phase 1/2
- Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast CancerTerminatedNCT03225547Phase 2
- Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)WithdrawnNCT03221634Phase 2
- Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.Active, not recruitingNCT03220477Phase 1
- Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of PembrolizumabCompletedNCT03212651Phase 2
- Study Comparing Pembrolizumab With Methotrexate in Elderly, Frail or Cisplatin-ineligible Patients With Head and Neck CancersTerminatedNCT03193931Phase 2
- Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine CancerCompletedNCT03192059Phase 2
- Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple MyelomaWithdrawnNCT03191981Phase 1/2
- Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell CarcinomasWithdrawnNCT03189186Phase 1
- Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory LymphomasActive, not recruitingNCT03179930Phase 2
- Special Combination of OBP-301 and PembrolizumabCompletedNCT03172819Phase 1
- Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung CancerWithdrawnNCT03166254Phase 1
- SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With PembrolizumabActive, not recruitingNCT03161431Phase 1
- Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)Active, not recruitingNCT03153202Phase 1/2
- A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer PatientsStatus unknownNCT03145961Phase 2
- Evaluation of Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic CyclophosphamideCompletedNCT03139851Phase 2
- Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDXCompletedNCT03134456Phase 4
- Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab TreatmentStatus unknownNCT03132675Phase 2
- Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN LossCompletedNCT03131908Phase 1/2
- Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian CancerCompletedNCT03126812Phase 1/2
- Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell CancerWithdrawnNCT03111901Phase 1/2
- Study of Pembrolizumab in Metastatic Biliary Tract Cancer as Second-line Treatment After Failing to at Least One Cytotoxic Chemotherapy Regimen: Integration of Genomic Analysis to Identify Predictive Molecular SubtypesCompletedNCT03110328Phase 2
- Treatment of Relapsed or Refractory Natural Killer/T Cell LymphomaStatus unknownNCT03107962Phase 2
- Pembrolizumab Plus Y90 Radioembolization in HCC SubjectsStatus unknownNCT03099564Early Phase 1
- A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the ExtremityActive, not recruitingNCT03092323Phase 2
- Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced MelanomaCompletedNCT03084640Phase 1
- Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer PatientsStatus unknownNCT03053856Phase 2
- Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid TumorsActive, not recruitingNCT03030378Phase 1
- Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube CancerActive, not recruitingNCT03029403Phase 2
- Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT03021460Phase 1
- Pembrolizumab for T/NK-cell lymphomasNK-cell LymphomasStatus unknownNCT03021057Phase 2
- A Study of Pembrolizumab in Patients With Relapsed Or Metastatic Osteosarcoma Not Eligible for Curative SurgeryTerminatedNCT03013127Phase 2
- Secured Access to Pembrolizumab for Patients With Selected Rare Cancer TypesCompletedNCT03012620Phase 2
- Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast CancerCompletedNCT03012230Phase 1
- Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast CancerTerminatedNCT02990845Phase 1/2
- A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV MelanomaStatus unknownNCT02990416Phase 1/2
- Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLCTerminatedNCT02987998Phase 1
- Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast CancerCompletedNCT02977468Phase 1
- CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck CancerActive, not recruitingNCT02955290Phase 1/2
- Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast CancerActive, not recruitingNCT02954874Phase 3
- Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT02950220Phase 1
- Anti PD-1 Neo-adjuvant Treatment for NSCLCCompletedNCT02938624Phase 1
- Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial TractTerminatedNCT02925533Phase 1
- Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid TumorsCompletedNCT02909452Phase 1
- Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant MelanomaCompletedNCT02902042Phase 1/2
- Pembrolizumab, Trastuzumab, HER2 Positive Gastric CancerStatus unknownNCT02901301Phase 1/2
- Study of Pembrolizumab as First Line Therapy in Patients With Unresectable Squamous Cell Carcinoma of the SkinCompletedNCT02883556Phase 2
- RADVAX™: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 MonotherapyWithdrawnNCT02880345Phase 1
- Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer PatientsCompletedNCT02879760Phase 1/2
- BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic MelanomaCompletedNCT02872259Phase 1/2
- Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)Active, not recruitingNCT02872025Early Phase 1
- Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)Active, not recruitingNCT02861573Phase 1/2
- Trial Of Pembrolizumab And NintedanibCompletedNCT02856425Phase 1
- Special Combination of BBI608 and PembrolizumabTerminatedNCT02851004Phase 1/2
- Trial of Stereotactic Body Radiotherapy With Concurrent Pembrolizumab in Metastatic Urothelial CancerCompletedNCT02826564Phase 1
- Pembrolizumab + CVA21 in Advanced NSCLCStatus unknownNCT02824965Phase 1
- X4P-001 and Pembrolizumab in Patients With Advanced MelanomaCompletedNCT02823405Phase 1
- Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced MelanomaTerminatedNCT02818023Phase 1
- Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic MelanomaCompletedNCT02816021Phase 2
- Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/AmplificationWithdrawnNCT02812693Phase 1/2
- Combination Adenovirus + Pembrolizumab to Trigger Immune Virus EffectsCompletedNCT02798406Phase 2
- Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL)Status unknownNCT02779101Phase 2
- Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell CarcinomaCompletedNCT02775812Phase 1
- Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and NeckActive, not recruitingNCT02769520Phase 2
- Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)Status unknownNCT02758587Phase 1/2
- CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal TumorsTerminatedNCT02757391Phase 1
- A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast CancerActive, not recruitingNCT02755272Phase 2
- Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder CarcinomaCompletedNCT02736266Phase 2
- Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung CancerCompletedNCT02733250Phase 1/2
- A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid TumorsCompletedNCT02722954Phase 1
- Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic MelanomaWithdrawnNCT02719015Phase 1/2
- Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid TumorsActive, not recruitingNCT02717156Phase 2
- A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural MesotheliomaTerminatedNCT02707666Phase 1
- Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCCCompletedNCT02707588Phase 2